Mechanisms for early microvascular injury in obesity and type II diabetes
- 55 Downloads
Obesity in the absence of hyperglycemia carries a low risk for microvascular disease compared with type II diabetes. The occurrence of hyperglycemia seems to be an important, if not the most important, distinction between obesity and obesity plus diabetes mellitus for microvascular disease. In vitro and in vivo human and animal studies of the early microvascular consequences of hyperglycemia indicate an immediate detrimental suppression of vasodilatory microvascular mechanisms that might be even worse with pre-existing obesity. The overall concept emerging from a very large research base is that hyperglycemia activates protein kinase C, increases oxidant formation, elevates constrictor prostanoid species to the detriment of beneficial prostanoids, and suppresses flow-mediated regulation with the nitric oxide generated by endothelial cells. The end result is decreased blood flow and loss of microvascular reactivity to endothelial-dependent vasodilatory stimuli that persists for 3 to 6 hours.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 4.Lash JM, Nase GP, Bohlen HG: Acute hyperglycemia depresses arteriolar NO formation in skeletal muscle. Am J Physiol 1980, 277:H1513-H1520.Google Scholar
- 6.Ihlemann N, Rask-Madsen C, Perner A, et al.: Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 2003, 285:H875-H882. This study illustrates that in normal humans, systemic hyperglycemia impairs endothelial-dependent vasodilation. This problem is negated by supplemental administration of tetrahydrobiopterin.PubMedGoogle Scholar
- 7.Beckman JA, Goldfine AB, Gordon MB, et al.: Inhibition of protein kinase C beta prevents impaired endotheliumdependent vasodilation caused by hyperglycemia in humans. Circ Res 2002, 90:107–111. This study demonstrates that endothelial-dependent vasodilation in humans is suppressed by acute hyperglycemia but, if pretreated to block protein kinase C beta, can avoid endothelial acute dysfunction.PubMedCrossRefGoogle Scholar
- 10.Bohlen HG, Nase GP: Obesity lowers hyperglycemic threshold for impaired in vivo endothelial nitric oxide function. Am J Physiol Heart Circ Physiol 2002, 283:H391-H397. This study in Zucker obese rats found that obesity lowered the glucose concentration required to inhibit nitric oxide production by endothelial cells to 200 mg/dL, the mechanism caused by excessive activation of PKC IIβ.PubMedGoogle Scholar
- 11.King GL, Kunisaki M, Nishio Y, et al.: Vitamin E normalizes diacylglycerol-protein kinase C activation induced by hyperglycemia in rat vascular tissues. Diabetes 1996, 45S:S117-S119.Google Scholar
- 12.Matsubara M, Hayashi N, Jing T, Titani K: Regulation of endothelial nitric oxide synthase by protein kinase C. J Biochem (Tokyo) 2003, 133:773–781. This is an excellent review of the interplay of protein kinase C with eNOS, which is likely a key issue in diabetes and obesity.Google Scholar
- 17.Way KJ, Katai N, King GL: Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001, 18:945–959. This review illustrates the biochemical and functional evidence that PKC activation is a major problem in diabetic vascular regulation and the pharmacologic approaches that have proven useful in animal models of diabetes.PubMedCrossRefGoogle Scholar
- 26.Sheetz MJ, King GL: Molecular understanding of hyperglycemia’s adverse effects for diabetic complications. JAMA 2002, 288:2579–2588. In this review, the four major mechanisms thought to impair cells during hyperglycemia and the pharmacologic approaches to suppress the mechanisms are considered.PubMedCrossRefGoogle Scholar
- 28.Huang A, Vita JA, Venema RC, Keaney JF Jr: Ascorbic acid enhances endothelial nitric-oxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000, 275:17399–17406. This study found that a large part of the beneficial effect of vitamin C to improve NO physiology is through increasing a cofactor for eNOS, tetrahydrobiopterin. This cofactor is likely suppressed by hyperglycemia.PubMedCrossRefGoogle Scholar